⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450553 | 0.70 | — | — | |
| SCHEMBL5739 | 0.65 | — | — | |
| SCHEMBL451671 | 0.65 | — | — | |
| SCHEMBL1646309 | 0.63 | ELANE (0.43) | — | |
| SCHEMBL7295091 | 0.63 | ELANE (0.43) | — | |
| SCHEMBL35607 | 0.62 | — | — | |
| SCHEMBL29815923 | 0.62 | — | — | |
| SCHEMBL17965512 | 0.61 | — | — | |
| SCHEMBL720139 | 0.61 | GPR3 (0.54) | — | |
| SCHEMBL1487929 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704114-B1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-23 | — | — | EP | claimed |
| US-11078198-B2 | Spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | claimed |
| EP-3704114-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | claimed |
| US-20190127362-A1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | claimed |
| EP-2188282-B1 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-01-23 | — | — | EP | claimed |
| US-20110263662-A1 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-27 | — | — | US | claimed |
| EP-2188282-A2 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-05-26 | — | — | EP | claimed |
| WO-2009022311-A2 | 1,2-DIAMIDO-ETHYLENE DERIVATIVES AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-19 | — | — | WO | claimed |
| US-5278169-A | Method of treating or prevention of fibrillation of the heart | E. R. SQUIBB & SONS, INC. (US) | 1994-01-11 | — | — | US | claimed |
| US-5202330-A | Hypotensive and cardiovascular agent, reduces blood pressure in mammals | E. R. SQUIBB & SONS, INC. (US) | 1993-04-13 | — | — | US | claimed |
| US-5143915-A | Hypotensive agents | E. R. SQUIBB & SONS, INC. (US) | 1992-09-01 | — | — | US | claimed |
| US-5140031-A | Pyranyl cyanoguanidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| EP-0253178-A1 | Substituted 1,5-benzodiazepine compounds | E.R. Squibb & Sons, Inc. (US) | 1988-01-20 | — | — | EP | claimed |
| US-4650797-A | HYPOTENSIVES | E. R. SQUIBB & SONS, INC. (US) | 1987-03-17 | — | — | US | claimed |
| US-4647561-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1987-03-03 | — | — | US | claimed |
| EP-0204317-A2 | 2-Thio or oxo-4-aryl or heterocyclo-1,5(2H)-pyrimidinedicarboxylic acid diesters and 3-acyl-5-pyrimidinecarboxylic acids and esters | E.R. Squibb & Sons, Inc. (US) | 1986-12-10 | — | — | EP | claimed |
| US-20240238460-A1 | IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF | TELIX PHARMACEUTICALS INNOVATIONS PTY LTD (AU) | 2024-07-18 | — | — | US | disclosed |
| US-12030866-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-0204317-A2 | 2-Thio or oxo-4-aryl or heterocyclo-1,5(2H)-pyrimidinedicarboxylic acid diesters and 3-acyl-5-pyrimidinecarboxylic acids and esters | E.R. Squibb & Sons, Inc. (US) | 1986-12-10 | — | — | EP | disclosed |
| EP-0202654-A2 | 5-Carboxy-1,4-dihydropyrimidine derivatives | E.R. Squibb & Sons, Inc. (US) | 1986-11-26 | — | — | EP | disclosed |